HFrEF – Medxy AI

Vericiguat in Compensated HFrEF: Navigating the Complex Results of the VICTOR Trial and the Burden of Outpatient Worsening

By MedXY 01/17/2026

The VICTOR trial evaluated vericiguat in stable HFrEF outpatients. While the primary endpoint was not met, exploratory analyses revealed significant mortality reductions and highlighted the prognostic importance of outpatient heart failure worsening, suggesting a broader clinical role for sGC stimulators.

Cardiology Nephrology news

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced

By MedXY 12/26/2025

This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electrolyte-stabilizing benefit of SGLT2 inhibitors.

Cardiology news

PDE9 Inhibition with CRD-740 Safely Elevates cGMP Levels in HFrEF: Results from the CARDINAL-HF Trial

By MedXY 12/26/2025

The Phase 2 CARDINAL-HF trial demonstrates that CRD-740, a novel PDE9 inhibitor, significantly increases plasma and urinary cGMP in patients with heart failure and reduced ejection fraction. The treatment was well tolerated and effective even alongside sacubitril/valsartan, suggesting a potential new therapeutic pathway.

Cardiology Nephrology news

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

By MedXY 11/29/2025

In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or therapy optimization.

Cardiology Clinical Updates news Specialties

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

By MedXY 10/10/2025

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with acceptable safety.

Cardiology Clinical Updates news Specialties

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

By MedXY 09/20/2025

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential for mortality risk reduction.

Cardiology Clinical Updates news Specialties

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

By MedXY 08/30/2025

The DIGIT-HF trial sheds new light on digitoxin's role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.

Cardiology news Specialties

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients

By MedXY 08/30/2025

The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glycoside under strict dosing protocols.